Download - Intuitive Surgical JP Morgan Presentation
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
1/25
JP Morgan Healthcare
Conference 2016
Gary GuthartPresident and CEO
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
2/25
Forward Looking Statement
These slides and any accompanying oral presentationby Intuitive Surgical, Inc. contain estimates and
forward-looking statements. Actual results may differ
materially from those expressed or implied as a result
of certain risks and uncertainties. These risks and
uncertainties are described in detail in the Companys
Securities and Exchange Commission filings.
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
3/25
Agenda
2015 Review
da Vinci Value
Opportunities/Catalysts
2016 Priorities
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
4/25
2015 Objectives Expanding da Vinciin general
surgery, particularly colorectal
surgery and hernia repair
Filling out our product line for
da VinciXiand launching in key
markets globally
Developing our organizational
capabilities and markets in
Europe and Asia Advancing our technologies to
improve surgery
Lowering our direct product costs
Areas of Strength
General surgery growth
International procedure
growth
da Vinci Xi product line
and feature set
Growing acceptance of
robotic -assisted surgery
Extensive, established
da Vinci ecosystem
Challenges Structural barriers in
some markets
Single-Siteprocedures
2015 Commentary
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
5/25
Worldwide Procedure Trend
0
100,000
200,000
300,000
400,000
500,000
600,000
700,000
800,000
2010 2011 2012 2013 2014 2015 2016
Urology Gynecology General Surgery Other
2015:
14% Growth
2016 Guidance:
9-12% Growth
Company estimates
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
6/25
0
100,000
200,000
300,000
400,000
500,000
2010 2011 2012 2013 2014 2015
Urology Gynecology General Surgery Other
+11%
US Procedure Trend
Company estimates
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
7/25Company estimates
OUS Procedure Trend
0
20,000
40,000
60,000
80,000
100,000
120,000
140,000
160,000
2010 2011 2012 2013 2014 2015
Europe Asia Rest of World
+26%
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
8/25
System Placement Trend by Region
0
20
40
60
80
100
120
140
160
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
2014 2015
U.S. Europe Asia Rest-of-World
2015 +14%
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
9/25
System Placement Trend by Platform
0
20
40
60
80
100
120
140
160
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
2014 2015
Xi Si S / Sie
2015 +14%
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
10/25
Total Revenue*
$0
$500
$1,000
$1,500
$2,000
$2,500
2010 2011 2012 2013 2014 2015
Systems Service Inst & Accy
2015
70%
Recurring
*Dollar amounts in millions
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
11/25
Annual Service Rev Per System
da VinciSurgical System ASP
Inst & Accy Rev Per Procedure
Multiple Segment Product Offering
$0.6M
$170K$100K
$3,200$700
$2.5M
da Vinci Si-e
Single-Site
Dual ConsoleXi
Firefly
Table Motion
Endowrist
Vessel Sealer
Stapler
2015: $1.54M
2015: $1,840
2015: $138K Dual ConsoleXida Vinci Si-e
Includes company estimates and approximate ranges
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
12/25
DA VINCI VALUE
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
13/25
Length of stay
Conversions to open surgery
Complications
Readmissions
Surgical site infections (SSI)
Instrument and accessory costs
Comprehensive Cost of Care
Capital costs
OR time costs
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
14/25
Family of da Vinci Systems ~1400 Skill Simulators,Dual Surgeon Consoles
3D HD Imaging,
Fluorescent Imaging
24/7/365
Comprehensive
Support
Integrated Energy,
Stapling, Vessel Sealing
40+Training
Course Offerings
10,000Peer-Reviewed Publications
1700+ Comparative Studies
Analytics and
Efficiency Programs
da Vinci Ecosystem
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
15/25
OPPORTUNITIES AND CATALYSTSFOR GROWTH
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
16/25
Open Surgery Remains CommonU.S.
Yr: 2004
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Prostate Malignant
Hyst
Benign Hyst
Robotic Other MIS Open
Source: ISI estimates and third party data
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
17/25
Open Surgery Remains CommonU.S.
Yr: 2015
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Prostate Malignant
Hyst
Benign Hyst
Robotic Other MIS Open
Source: ISI Data as well as Estimates
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
18/25
Open Surgery Remains CommonU.S.
Yr: 2015
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Prostate Malignant
Hyst
Benign Hyst Colorectal Ventral
Hernia
Thoracic
Robotic Other MIS Open
Source: ISI estimates and third party data
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
19/25
Total Procedure Markets
As many as 4 million procedures available forproducts on the market today in countries for
which we have clearances
Over time, international opportunity will begreater than U.S.
Roughly half of opportunity based on
underlying cancer as cause
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
20/25
ISI Investments
Advanced imaging
Advanced instrumentation and computer-
enhanced precision at tissue
Less invasive access Training technologies
Next generation robotic technologies
International organization
Continued clinical and economic validation
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
21/25
Building da Vinci Xi Value:
NewXiProducts / Markets
Vessel Sealer andFirefly launched 2014
Korea Clearance Q4 14
45 mmStapler launched Q1 15
Clearance in Japan end of Q1 15 Harmonic curved shears and other new
instruments FDA Cleared Q215
Table motion CE Marked and 510(k)
submitted in Q2 15 Single-Site510(k) submitted Q3 15
30 mm Stapler 510(k) submitted Q3 15
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
22/25
da Vinci Sp
Video plays at an accelerated speed.
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
23/25
2016 PRIORITIES
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
24/25
2016 Priorities
Expand da Vinci in thoracic and general surgery,particularly colorectal surgery and hernia repair
Advance key technologiesextend our product
leadership position
Drive international performance and strengthen
our organization
Maximize total-cost-to-treat value for customers
-
7/25/2019 Intuitive Surgical JP Morgan Presentation
25/25